Home  |  Contact

Cellosaurus PEA2 (CVCL_2683)

[Text version]

Cell line name PEA2
Accession CVCL_2683
Resource Identification Initiative To cite this cell line use: PEA2 (RRID:CVCL_2683)
Comments Part of: MD Anderson Cell Lines Project.
Part of: OCCP ovarian cancer cell line panel.
Doubling time: 66 hours (PubMed=3167863).
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Sequence variations
  • Mutation; HGNC; 952; BARD1; Simple; p.Trp218Ter (c.653G>A); ClinVar=VCV000482781; Zygosity=Unspecified (PubMed=25230021).
  • Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); Zygosity=Unspecified (PubMed=25230021).
Disease Ovarian cystadenocarcinoma (NCIt: C5228)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_2682 ! PEA1
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ECACC; PubMed=25230021; PubMed=30485824

Markers:
AmelogeninX
CSF1PO11,14
D2S133819
D3S135816
D5S81811,13
D7S82010,12
D8S117914
D13S3178
D16S53912,13
D18S5117
D19S43312,13
D21S1130
FGA25
Penta D13,15
Penta E7,13
TH019
TPOX8 (ECACC)
8,12 (PubMed=25230021; PubMed=30485824)
vWA17,18

Run an STR similarity search on this cell line
Web pages https://tcpaportal.org/mclp/
Publications

PubMed=3167863
Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A., Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Cancer Res. 48:6166-6172(1988)

PubMed=20581869; DOI=10.1038/onc.2010.245
Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J., Langdon S.P., Huntsman D.G., Brenton J.D.
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Oncogene 29:4905-4913(2010)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=25230021; DOI=10.1371/journal.pone.0103988
Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M., Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J., Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J., Helleman J.
Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.
PLoS ONE 9:E103988-E103988(2014)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

PubMed=35028612; DOI=10.1016/j.xcrm.2021.100471
Huang D.-Q., Chowdhury S., Wang H., Savage S.R., Ivey R.G., Kennedy J.J., Whiteaker J.R., Lin C.-W., Hou X.-N., Oberg A.L., Larson M.C., Eskandari N., Delisi D.A., Gentile S., Huntoon C.J., Voytovich U.J., Shire Z.J., Yu Q., Gygi S.P., Hoofnagle A.N., Herbert Z.T., Lorentzen T.D., Calinawan A., Karnitz L.M., Weroha S.J., Kaufmann S.H., Zhang B., Wang P., Birrer M.J., Paulovich A.G.
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Cell Rep. Med. 2:100471.1-100471.32(2021)

Cross-references
Cell line collections ECACC; 10032307
Ximbio; 151679
Cell line databases/resources Cell_Model_Passport; SIDM01425
Encyclopedic resources Wikidata; Q54946893
Gene expression databases GEO; GSM459852
GEO; GSM659401
GEO; GSM2474997
GEO; GSM4973220
GEO; GSM4973226
GEO; GSM4973232
GEO; GSM4973238
GEO; GSM4973250
GEO; GSM4973262
GEO; GSM4973244
GEO; GSM4973256
GEO; GSM4973268
Polymorphism and mutation databases Progenetix; CVCL_2683
Proteomic databases PRIDE; PXD020764
Entry history
Entry creation04-Apr-2012
Last entry update17-Mar-2022
Version number21